Lupus Science & Medicine

Increasing the utilisation of hydroxychloroquine blood level testing in lupus: a quality improvement project

Objective Hydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, ...
Lupus Science & Medicine

Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study

Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist ...
Lupus Science & Medicine

Qualitative interview study in patients with SLE to assess patient perception of fatigue and skin-related symptoms

Objective SLE is a chronic autoimmune disorder with a range of symptoms. While these are broadly reported in the literature, ...
Lupus Science & Medicine

Are RAS inhibitors necessary during intensive immunosuppression for lupus nephritis? Real-world evidence from the STAR cohort

Objective While guidelines advocate renin-angiotensin system inhibitors (RASi) for renoprotection in lupus nephritis (LN), ...
lupus.bmj

Remission and low disease activity state in childhood-onset systemic lupus erythematosus: differential impact on damage accrual in a Latin American cohort (GLADEL)

Objective To examine the impact of different disease activity states (DAS) on outcomes in a longitudinal inception childhood-onset SLE cohort. Materials and methods Three DAS were included—remission: ...
lupus.bmj

Influence of sex and systemic lupus erythematosus disease status on cerebral cortex structure

Objective To investigate the main and interactive effects of sex and disease diagnosis on cortical morphology in systemic lupus erythematosus (SLE), providing neuroimaging evidence for sex-by-disease ...
lupus.bmj

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered ...

Objective To determine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneously administered mosunetuzumab, a CD20xCD3 T-cell-engaging bispecific antibody, in ...
lupus.bmj

Stage-resolved mapping of RP105 (CD180)-negative B cells reveals residual plasmablast-lineage skewing in SLE: a cross-sectional study

Objective To determine whether clinically inactive/low-activity SLE reflects immunological remission in this cross-sectional study using CD180 (RP105)-anchored, stage-resolved profiling of peripheral ...
lupus.bmj

Predictors of damage accrual in childhood-onset SLE: a retrospective analysis from a tertiary lupus centre in Türkiye

Introduction SLE is a chronic autoimmune disease characterised by multisystem involvement and fluctuating clinical course, often leading to permanent organ damage. Childhood-onset SLE (cSLE) tends to ...
lupus.bmj

Belimumab induces early and sustained resolution of lupus thrombocytopenia

Objective Belimumab has well-established efficacy in improving overall SLE disease activity and preventing flares and organ damage. Belimumab effects have been demonstrated across organ domains but ...
lupus.bmj

Development of a LASSO-based machine learning model for relapse prediction in lupus nephritis

Objective To identify the predictors of renal relapse in patients with lupus nephritis (LN) and develop a predictive model. Methods The patients with LN who received renal biopsies from 2005 to 2024 ...
lupus.bmj

Belimumab as a possible treatment for SLE-associated pulmonary arterial hypertension: the experience from a single centre

Objective To explore clinical outcomes associated with belimumab use in patients with SLE-associated pulmonary arterial hypertension (SLE-PAH). Methods We performed an ambispective cohort study of 10 ...